A carregar...
Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of...
Na minha lista:
| Publicado no: | Case Rep Hematol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5097796/ https://ncbi.nlm.nih.gov/pubmed/27843657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2389038 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|